Document:

Exhibit 10.2

 

		C3J Therapeutics, Inc.
	4503 Glencoe Avenue	(310) 665-2928 Tel.
	Marina del Rey, CA 90292	(310) 665-2963 Fax.
	www.c3-jian.com	 

 

 

	Mr. Todd Patrick	October 1, 2018
	9029 NE 36th Street	 
	Yarrow Point, WA 98004	 

 

Re: Extension of your Employment Agreement

 

Dear Todd:

 

On behalf of C3J Therapeutics,
Inc., (the "Company"), I am pleased to confirm the continued employment of you as the Company’s President and Chief
Executive Officer, reporting to our board of directors (the "Board"). This letter sets out the terms of your employment
with the Company, which will continue uninterrupted in the same manner as you have been employed since November 1, 2010, subject
now to the terms of this letter starting on October 1, 2018 the ("Start Date").

 

You will be paid an annual
Base Salary of $412,000 for each year (payable bi-weekly) less applicable tax and other withholdings. Other than as outlined below,
any future adjustments to compensation, if any, will be made by the Company in its sole discretion. You may also be eligible to
earn an annual cash bonus, in accordance with a milestone based structure to be established by the Board, enabling you to earn
between 50% and 100% of the amount of your Base Salary based on your achievement of such milestones, as determined by the Board
in its sole discretion. You must be an employee of the Company on December 31st of a particular calendar year in order to be eligible
to receive a cash bonus for such year.

 

Upon the completion of
a corporate partnership, equity financing, debt, grants or a combination of one or more of various financing structures, sufficient
to fund the Company for at least twenty-four (24) months, your Base Salary shall be increased to $550,000 paid retroactively to
January 1, 2018. The increased Base Salary and retroactive payment must be included in the calculation when determining whether
the funds received provides a 24 month run way for the Company.

 

All stock options and Restricted
Share Awards that you have previously been granted will continue in effect. There are no new grants or awards in connection with
this revised employment agreement.

 

As President and Chief Executive Officer, you also agree to serve as the "then-sitting
Chief Executive Officer" member of the Board in accordance with Section 3.1(e) of that certain Second Amended and Restated
Investors' Rights Agreement by and among the Company and the other parties thereto, dated December 21, 2009.

 

     

     

    

 

		C3J Therapeutics, Inc.
	4503 Glencoe Avenue	(310) 665-2928 Tel.
	Marina del Rey, CA 90292	(310) 665-2963 Fax.
	www.c3-jian.com	 

 

You will also be eligible
for all fringe benefit plans available to other full-time Company employees, including health and dental insurance coverage for
you, your spouse and your dependent children, 40l(k) plan and benefit programs, in accordance with the Company's benefit plans
and policies. You will receive 5 weeks of vacation annually. To the extent that you do not use all of your vacation in a given
year, you will be permitted to accrue up to a cap of 1.5 times your annual accrual rate of vacation, at which time you will cease
accruing any vacation until you use some and drop below the cap. The Company reserves the right to change or eliminate these benefits
on a prospective basis at any time.

 

As a condition of your
employment, the Company's standard form of employee nondisclosure and assignment agreement, which you have already executed, will
remain in full force and effect.

 

The term of this employment
agreement is for three (3) years from the start date of October 1, 2018. If the Company terminates you without Cause (as defined
in the stock option plan) or you resign for Good Reason (as defined below), then the Company shall compensate you with a severance
payment equal to your Base Salary plus 50% bonus (the bonus to be paid whether earned or unearned) for the then remaining term
of this contract, or through September 30, 2021. Such payment to be lengthened to a minimum of one year or twelve (12) months of
Base Salary and bonus, if your termination occurs during any month during the 2021 calendar year. Any such severance payment will
be made in full at the next normal payroll period of the Company, less applicable taxandother withholdings.

 

"Good
Reason" shall mean your resignation due to either a) a Change of Control or in the event of a consolidation or
merger with a third party even if there is no Change of Control (in either case a “Corporate Transaction”) or b)
either of the following (i) a material diminution of your title, position, duties or responsibilities; or (ii) the involuntary
relocation of your primary office location to more than fifty (50) miles from your present home in Yarrow Point, WA.

 

If in the reasonable opinion
of the Board, the severance payment outlined above would have a negative impact on a potential Corporate Transaction, then you
and the Board will work out a payment schedule that could extend the severance payments to match monthly payments running the full
length of this agreement. In this case, you will continue to earn fringe benefits for the length of the agreement and will be offered
a prestigious position (board or consulting) in the new entity that results from the Corporate Transaction.

 

In the event of any dispute or claim relating
to or arising out of your employment relationship with the Company, this agreement, or the termination of your employment with
the Company for any reason (including, but not limited to, any claim of breach of contract, defamation, wrongful termination or
age, sex, sexual orientation, race, color, national origin, ancestry, marital status, religious creed, physical or mental disability
or medical condition or other discrimination, retaliation or harassment), you and the Company agree that such dispute or claim
shall be fully resolved by confidential, binding arbitration conducted by a single arbitrator through the American Arbitration
Association ("AAA") under the AAA's National Rules for the Resolution of Employment Disputes then in effect, which are
available online at the AAA's website at www.adr.org. You and the Company hereby waive your respective rights to have any such
dispute or claim tried before a judge or jury.

 

     

     

    

 

		C3J Therapeutics, Inc.
	4503 Glencoe Avenue	(310) 665-2928 Tel.
	Marina del Rey, CA 90292	(310) 665-2963 Fax.
	www.c3-jian.com	 

 

This agreement, and
the non-disclosure and assignment agreement referred to above, constitute the entire agreement between you and the Company
regarding the terms and conditions of your employment, and they supersede all prior negotiations, representations or
agreements between you and the Company (with the exception of your existing stock option agreements, Restricted Share Award
agreements, which shall remain in force in accordance with their terms). The provisions of this agreement may only be
modified by a document signed by you and an authorized representative of the Company.

 

This agreement shall be binding upon you and the Company and any
its successors or assigns. This agreement will be binding upon the remaining entity resulting from any Corporate Transaction.

 

Todd, we look forward to continuing your role as the full-time leader
of the management team at C3J Therapeutics and our wholly owned subsidiary C3 Jian, LLC. Please sign and date this letter in the
space provided below to acknowledge your acceptance of the terms of this agreement.

 

	Sincerely, C3J Therapeutics, Inc.	 
	 	 
	By, 	/s/ H. Stewart Parker	 
	 	 
	H. Stewart Parker	 
	Chair of the Board of Directors	 
	 	 	 

I agree to and accept employment with C3J Therapeutics,
Inc. on the terms and conditions set forth in this letter agreement, effective as of October 1, 2018.

 

	Date: October 1, 2018	 
	 	 
	/s/ Todd Patrick	 
	Todd PatrickExhibit 10.3

 

AMENDMENT
TO

EMPLOYMENT
AGREEMENT

 

The
Employment Agreement between C3J Therapeutics, Inc. (the “Company”)
and Todd Patrick (“Executive”)
dated as of October 1, 2018 (the “Agreement”)
is hereby amended, effective as of the “Effective Time”, as defined in the Agreement and Plan of Merger and Reorganization
dated as of January 3, 2019, by and among AmpliPhi Biosciences Corporation, Ceres Merger Sub, Inc. and the Company, as follows:

 

		1.	The tenth paragraph of the Agreement is hereby deleted
in its entirety and replaced with the following:

 

“The
severance pay provided in this agreement is intended to qualify for an exemption from application of Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of
similar effect (collectively “Section 409A”) or to comply with its requirements to the extent necessary to avoid adverse
personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. Each installment of
severance pay is a separate “payment” for purposes of Section 409A. If no exemptions to Section 409A are available
and you are, upon separation from service, a “specified employee” for purposes of Section 409A, then, solely to the
extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the severance pay shall be delayed
until the earlier of (i) six (6) months and one day after your separation from service, or (ii) your death. Except to the minimum
extent that payments must be delayed because you are a “specified employee”, all amounts of severance pay will be paid
as soon as practicable in accordance with the schedule provided herein and in accordance with the Company’s normal payroll
practices.”

 

		2.	Except as explicitly set forth herein, the Agreement
will remain in full force and effect.

 

IN
WITNESS WHEREOF, the parties have executed this amendment effective as of the date written above.

 

	 	C3J THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/ H Stewart Parker / Board Chair
	 	 	H Stewart Parker
	 	 	 
	 	EXECUTIVE
	 	 	 
	 	/s/ Todd Patrick
	 	Todd Patrick

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]